生物制剂对慢性鼻窦炎伴鼻息肉和变应性真菌性鼻窦炎手术的影响
本研究基于TriNetX数据库,比较度普利尤单抗、奥马珠单抗和美泊利单抗对慢性鼻窦炎伴鼻息肉(CRSwNP)和变应性真菌性鼻窦炎(AFRS)患者功能性内镜鼻窦手术(FESS)绝对风险降低(ARR)的影响。倾向性评分匹配后,所有单抗均降低CRSwNP患者FESS风险,但仅度普利尤单抗还降低住院、急诊就诊和急性鼻窦炎风险;在AFRS患者中,仅度普利尤单抗改善所有结局。
要点
- 在CRSwNP患者中,度普利尤单抗、奥马珠单抗和美泊利单抗均降低FESS风险。
- 仅度普利尤单抗还降低CRSwNP患者住院、急诊就诊和急性鼻窦炎风险。
- 在AFRS患者中,仅度普利尤单抗降低FESS、住院、急诊就诊和急性鼻窦炎风险。
核心结论
- 所有单抗均降低CRSwNP患者FESS风险,但仅度普利尤单抗还降低次要结局。
- 在AFRS患者中,仅度普利尤单抗改善所有结局,提示单抗有潜力减轻疾病负担并改善患者结局。
研究设计与样本
- 查询TriNetX研究网络数据库,涵盖每种单抗上市至2024年3月的数据。
- 成人CRSwNP患者按年龄、性别、种族和哮喘诊断与非单抗对照进行倾向性评分匹配。
- 主要结局为FESS率,次要结局包括住院、急诊就诊和急性鼻窦炎发生率;对AFRS患者进行亚组分析。
主要发现
- 在CRSwNP患者中,度普利尤单抗降低FESS风险(ARR 11.48%,95% CI 9.82%-13.15%,p < 0.001)。
- 在CRSwNP患者中,奥马珠单抗降低FESS风险(ARR 12.02%,95% CI 4.36%-19.68%,p = 0.002)。
- 在CRSwNP患者中,美泊利单抗降低FESS风险(ARR 10.32%,95% CI 5.24%-15.40%,p < 0.001)。
- 在CRSwNP患者中,仅度普利尤单抗降低住院(ARR 8.59%,95% CI 7.04%-10.15%,p < 0.001)、急诊就诊(ARR 5.94%,95% CI 4.28%-7.61%,p < 0.001)和急性鼻窦炎(ARR 2.60%,95% CI 1.09%-4.12%,p = 0.001)风险。
- 在AFRS患者中,仅度普利尤单抗降低FESS(ARR 6.97%,95% CI 2.86%-11.09%,p = 0.001)、住院(ARR 16.93%,95% CI 11.30%-22.57%,p < 0.001)、急诊就诊(ARR 13.15%,95% CI 7.15%-19.14%,p < 0.001)和急性鼻窦炎(ARR 7.17%,95% CI 2.18%-12.17%,p = 0.005)风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of th2-targeted biologic medications (dupilumab, omalizumab, and mepolizumab) on absolute risk reduction (ARR) of functional endoscopic sinus surgery (FESS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and allergic fungal rhinosinusitis (AFRS). METHODS: The TriNetX Research Network database was queried for each mAb's market lifespan through March 2024. Adults with CRSwNP were propensity score matched against non-mAb controls based on age, sex, race, and asthma diagnosis. The primary outcome was rate of FESS, with secondary outcomes including inpatient admission, emergency department (ED) visit, and incidence of acute sinusitis. Subgroup analysis was performed for patients with AFRS. RESULTS: All mAbs decreased FESS risk (dupilumab, ARR 11.48%, 95% CI 9.82%-13.15%, p < 0.001; omalizumab, ARR 12.02%, 95% CI 4.36%-19.68%, p = 0.002; mepolizumab, ARR 10.32%, 95% CI 5.24%-15.40%, p < 0.001) in CRSwNP patients. Only dupilumab also reduced risk of inpatient admission (ARR 8.59%, 95% CI 7.04%-10.15%, p < 0.001), ED visit (ARR 5.94%, 95% CI 4.28%-7.61%, p < 0.001), and acute sinusitis (ARR 2.60%, 95% CI 1.09%-4.12%, p = 0.001). In AFRS patients, only dupilumab reduced the risk of all outcomes: FESS (ARR 6.97%, 95 CI 2.86%-11.09%, p = 0.001), inpatient admission (ARR 16.93%, 95% CI 11.30%-22.57%, p < 0.001), ED visit (ARR 13.15%, 95% CI 7.15%-19.14%, p < 0.001), and acute sinusitis (ARR 7.17%, 95% CI 2.18%-12.17%, p = 0.005). CONCLUSION: Although all mAbs reduced FESS risk in CRSwNP, only dupilumab reduced secondary outcomes as well. Similarly, only dupilumab improved all outcomes in AFRS patients. These data demonstrate the potential of mAbs in reducing disease burden and enhancing patient outcomes in CRSwNP and AFRS. LEVEL OF EVIDENCE: NA Laryngoscope, 135:593-601, 2025.
引用
- Bentan MA, Pingree G, Lee L, et al. Impact of Biologics on Surgery in Chronic Rhinosinusitis with Polyps and Allergic Fungal Sinusitis. Laryngoscope. 2024. PMID: 39290040. doi:10.1002/lary.31774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。